Analyze Diet

The effects of food on the pharmacokinetics of mycophenolate mofetil in healthy horses.

Abstract: Additional immunomodulatory treatment is needed for the management of immune-mediated disease in horses. Mycophenolate mofetil (MMF) is an immunomodulatory agent used in human and veterinary medicine for the prevention of graft rejection and the management of autoimmune diseases. Few studies exist investigating the pharmacokinetics of MMF in horses. The aim of this study was to evaluate the pharmacokinetics of a single dose of MMF in healthy horses in the fed vs. fasted state. Six healthy Standardbred mares were administered MMF 10 mg/kg by a nasogastric (NG) tube in a fed and fasted state. A six-day washout period was performed between the two doses. No statistically significant differences in mycophenolic acid (MPA) concentrations were seen at any time point apart from 8 h, when plasma metabolite concentrations were significantly higher in the fasted state compared to the fed state (p = .038). Evidence of enterohepatic recirculation was seen only in the fasted state; this did not yield clinical differences in horses administered a single-dose administration but may be significant in horses receiving long-term MMF treatment.
Publication Date: 2024-02-09 PubMed ID: 38334367DOI: 10.1111/jvp.13430Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research studies the changes in absorption rate of the drug mycophenolate mofetil (MMF) in horses given the medicine in a fed and fasted state. The study found that a single dose administration of MMF in a fasted state resulted in higher plasma metabolite concentrations than in a fed state at a certain time point.

Research Purpose and Methodology

  • The primary objective of this study was to explore the pharmacokinetics, that is, the body’s process of absorbing, distributing, metabolising, and excreting a drug, of MMF in healthy horses under the conditions of being fed and fasted.
  • The drug MMF, which is commonly used in human and veterinary medicine to prevent graft (transplant) rejection and managing autoimmune disorders, was administered at a 10 mg/kg dosage through a nasogastric (NG) tube to six healthy Standardbred mare horses in both states.
  • To ensure elimination of the drug before switching states, a six-day washout period was employed between the two administrations.

Study Findings

  • There was no statistically significant disparity in the concentrations of mycophenolic acid (MPA), a metabolite of MMF, at any point in time except for 8 hours post administration. During this period, significantly higher MPA levels were observed in the horses when fasted compared to when fed.
  • This suggests that the feeding conditions of the horse might influence the pharmacokinetics of MMF, specifically its absorption rate in the digestive system.
  • In the fasted state, evidence of enterohepatic recirculation was found, which refers to the process where the drug, after being metabolised in the liver, is excreted into the bile, reabsorbed in the intestine, and returned to the liver. This cycle was not observed in the fed state.
  • While this enterohepatic recirculation did not trigger noticeable clinical differences in horses given a single dose, the study suggests it may have significant implications for horses under long-term treatment with MMF.

Implications of the study

  • This study contributes to the limited body of research investigating the pharmacokinetics of MMF in horses, and provides crucial information that could assist in optimising dosage strategies.
  • Further investigations are needed to understand how variations in feeding states may affect longer term MMF treatment in horses suffering from immune-mediated diseases.

Cite This Article

APA
Bello K, Lorch G, Papich MG, Kim K, Toribio RE, Yan L, Xie Z, Hill K, Phelps MA. (2024). The effects of food on the pharmacokinetics of mycophenolate mofetil in healthy horses. J Vet Pharmacol Ther. https://doi.org/10.1111/jvp.13430

Publication

ISSN: 1365-2885
NlmUniqueID: 7910920
Country: England
Language: English

Researcher Affiliations

Bello, Kaitlyn
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
Lorch, Gwendolen
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
Papich, Mark G
  • Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Kim, Kyeongmin
  • Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Toribio, Ramiro E
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
Yan, Liwei
  • Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Xie, Zhiliang
  • Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Hill, Kasey
  • Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Phelps, Mitch A
  • Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.

Grant Funding

  • The Grayson-Jockey Club Research Foundation

References

This article includes 22 references
  1. Abd Rahman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clinical Pharmacokinetics 52(5), 303-331.
    doi: 10.1007/s40262-013-0039-8google scholar: lookup
  2. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 14, S2-S8.
    doi: 10.1191/0961203305lfoagoogle scholar: lookup
  3. Amstutz K, Schwark WS, Zakharov A, Gomez B, Lyubimov A, Ellis K, Venator KP, Wakshlag JJ. Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. Journal of Veterinary Pharmacology and Therapeutics 45(3), 245-254.
    doi: 10.1111/jvp.13048google scholar: lookup
  4. Baggot JD. Bioavailability and bioequivalence of veterinary drug dosage forms, with particular reference to horses: An overview. Journal of Veterinary Pharmacology and Therapeutics 15(2), 160-173.
  5. Bermingham E, Davis JL, Whittem T. Study design synopsis: Designing and performing pharmacokinetic studies for systemically administered drugs in horses. Equine Veterinary Journal 52(5), 643-650.
    doi: 10.1111/evj.13312google scholar: lookup
  6. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. British Journal of Clinical Pharmacology 41(6), 513-516.
  7. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clinincal Pharmacokinetics 34(6), 429-455.
  8. Burroughs DL, Lorch G, Guo YZ, Hill K, Schroeder EL, Cole LK, Phelps MA. Noncompartmental pharmacokinetics of three intravenous mycophenolate mofetil concentrations in healthy standardbred mares. Veterinary Dermatology 34, e13109.
    doi: 10.1111/vde.13109google scholar: lookup
  9. Cummings FO, Rizzo SA. Treatment of presumptive primary immune-mediated thrombocytopenia with mycophenolate mofetil versus cyclosporine in dogs. Journal of Small Animal Practice 58(2), 96-102.
    doi: 10.1111/jsap.12621google scholar: lookup
  10. Dewey CW, Cerda-Gonzalez S, Fletcher DJ, Harb-Hauser MF, Levine JM, Badgley BL, Olby NJ, Shelton GD. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008). Javma-Journal of the American Veterinary Medical Association 236(6), 664-668.
    doi: 10.2460/javma.236.6.664google scholar: lookup
  11. Gensburger O, Picard N, Marquet P. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clinical Chemistry 55(5), 986-993.
  12. Grobman M, Boothe DM, Rindt H, Williamson BG, Katz ML, Coates JR, Reinero CR. Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. Journal of Veterinary Pharmacology and Therapeutics 40(6), e1-e10.
    doi: 10.1111/jvp.12420google scholar: lookup
  13. Knych HK, McKemie DS, Kanarr KL, White SD. Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. American Journal of Veterinary Research 82(6), 502-509.
  14. Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: Mycophenolic acid pathway. Pharmacogenetics and Genomics 24(1), 73-79.
  15. Leclere M. Corticosteroids and immune suppressive therapies in horses. The Veterinary Clinics of North America. Equine Practice 33(1), 17-27.
  16. Martinez MN, Papich MG, Fahmy R. Impact of gastrointestinal differences in veterinary species on the oral drug solubility, in vivo dissolution, and formulation of veterinary therapeutics. ADMET DMPK 10(1), 1-25.
    doi: 10.5599/admet.1140google scholar: lookup
  17. Orvis AK, Wesson SK, Breza TS, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. Journal of the American Academy of Dermatology 60(2), 183-199.
  18. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clinincal Pharmacokinetics 41(10), 751-790.
  19. Slovak JE, Mealey K, Court MH. Comparative metabolism of mycophenolic acid by glucuronic acid and glucose conjugation in human, dog, and cat liver microsomes. Journal of Veterinary Pharmacology and Therapeutics 40(2), 123-129.
    doi: 10.1111/jvp.12338google scholar: lookup
  20. Wang A, Smith JR, Creevy KE. Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011). Journal of Small Animal Practice 54(8), 399-404.
    doi: 10.1111/jsap.12107google scholar: lookup
  21. Whitley NT, Day MJ. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. Journal of Small Animal Practice 52(2), 70-85.
  22. Zhou X, Cassidy KC, Hudson L, Mohutsky MA, Sawada GA, Hao J. Enterohepatic circulation of glucuronide metabolites of drugs in dog. Pharmacology Research & Perspectives 7(4), e00502.
    doi: 10.1002/prp2.502google scholar: lookup

Citations

This article has been cited 0 times.